PTC Therapeutics | PTCT - Assets


PTC Therapeutics reported $3.21B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.79B 51.25M Sep/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Amgen USD 96.05B 409M Sep/2026
BioCryst Pharmaceuticals USD 591.07M 33.22M Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
Cytokinetics USD 1.82B 99.77M Sep/2026
Daiichi Sankyo JPY 4.26T 144.08B Sep/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Gilead Sciences USD 51.41B 2.05B Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
Ionis Pharmaceuticals USD 2.91B 81.91M Sep/2026
Ironwood Pharmaceuticals USD 290.59M 5.46M Sep/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Novartis USD 117.15B 4.88B Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Roche Holding CHF 98.2B 2.5B Jun/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 3.17B 22.45M Sep/2026
TG Therapeutics USD 1.59B 47.38M Sep/2026
Ultragenyx Pharmaceutical USD 1.19B 77M Sep/2026
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026
Xencor USD 770.5M 45.54M Sep/2026